



**INTERNATIONAL FEDERATION OF FERTILITY SOCIETIES**

# Preimplantation Genetic Diagnosis Clinical and Laboratory Aspects

IFFS Embryology Workshop  
TARTU, ESTONIA  
21-23 September 2018

*This presentation is made possible, in part, with the generous non-restricted educational grant support from our sponsor for this workshop:*



[www.iffs-reproduction.org](http://www.iffs-reproduction.org)



@IntFertilitySoc



Int@FedFertilitySoc

# Preimplantation Genetic Tests

## Preimplantation Genetic **Diagnosis** (PGD)

- Test for a specific mutation or chromosomal abnormality, where there is a known risk due to **parental abnormality**
- Includes tests for **known** translocations

## Preimplantation Genetic **Screening** (PGS) or **Testing** (PGT)

- Test for aneuploidies, where prospective parents do not have a **known** genetic abnormality but may be considered at risk, eg
  - due to age
  - previous aneuploid pregnancy



# Preimplantation Genetic Diagnosis

Is for those who **know** they have a significant chance of a pregnancy that has inherited a serious genetic disorder, and who wish to avoid that risk



# Key points for patients considering PGD

- Couples **must** be seen by **clinical geneticist** in order to:
  - Confirm genetic diagnosis
  - Understand inheritance risk
  - Calculate risk within family
  - **Review reproductive options including PGD**
- For single gene disorders, PGD is only possible if the gene mutation has been identified
  - Linkage studies may be used
  - May not be possible eg for some rare metabolic disorders



# Preimplantation Genetic Screening

**PGS** is for those who **hope** they may have an increased chance of achieving a pregnancy with ART if their embryos are screened for any **sporadic** chromosomal abnormalities they may have, and only those free of abnormalities are transferred

While used widely internationally, PGS remains a **theoretically** beneficial treatment



# Key points when considering PGS

- In PGS, no specific diagnosis is tested for
- The parents are presumed to be normal and embryos are tested for abnormalities in chromosome numbers
- Most numerical chromosome abnormalities are **sporadic**
  - Usually result in miscarriage
  - **This is used as argument in support of PGS**
  - Efficacy still a matter for debate



# Main indications cited for PGS

- **Advanced maternal age** (usually defined as maternal age over 37 or 38 years)
- **Repeated implantation failure** (usually defined as  $\geq 3$  failed embryo transfer procedures with good quality embryos)
- **Recurrent miscarriage** in patients with normal karyotypes (usually at least three previous miscarriages)
- **Severe male factor** infertility



# NHS Clinical Commissioning Policy (2014)

*“In the absence of evidence of its clinical and cost effectiveness, there is no intention to support the introduction of PGS into NHS clinical practice”*






# Basic Genetics


## 1. Chromosome Abnormalities

- Abnormal copy number
  - Polyploidies eg triploidy
  - Monosomies
  - Trisomies (eg 21, 13, 18)
- Sex chromosome abnormalities
- Chromosome rearrangements
  - Deletions
  - Translocations
    - Reciprocal
    - Robertsonian



# Chromosomal abnormalities:


## Translocation



# Chromosomal abnormalities:

Segregation of  
translocations at  
meiosis

Genotype of gametes



# Chromosomal Abnormalities

## Segregation of translocations at meiosis

Theoretically, chromosomal constitutions in secondary oocytes could be:


- 16 different (reciprocal) translocations
- 6 different (Robertsonian) translocations
- **Only 2 of them are balanced**
- Which means 14 out of 16 (87%) are **unbalanced**



# Basic Genetics


## 2. Genetic mutations

- Autosomal dominant conditions
  - Affect 1:200 people
  - Single mutation in 1 copy of gene pair
  - Examples: Huntington's; myotonic dystrophy
  - **1:2 risk for children**
- Autosomal recessive conditions
  - Much rarer
  - Risk only if both parents are carriers
  - Examples: cystic fibrosis; spinal muscular atrophy
  - **1:4 risk for children**
- X-linked inheritance
  - Females carriers; 50% chance of passing to son
  - **Males affected**




# Monogenic Autosomal Dominant Disorders

## Classic Mendelian Inheritance



**Disease-Causing Allele**

50% chance of inheritance



**One parent carrier** may have mild/minor/no symptoms, or late onset


**Offspring** may have more severe symptoms depending on penetrance and expressivity

# Monogenic Autosomal Recessive Disorders

## Classic Mendelian Inheritance



**Disease-Causing Allele**  
25% chance of inheritance




Both parents **carriers**  
Usually no symptoms

1:4 pregnancies severe symptoms/disorder



# Family History: Autosomal recessive disorders



Great, great, great, great granduncle was the previous affected family member

24 family members did not meet another carrier



# Genetic Counselling and its role in PGD

Specialist counselling, separate from Fertility Counselling

- Family history and reason for requesting PGD
- Understand genetic risk
- Explore alternative reproductive options
- Understand PGD process, physical and emotional impact, and chance of successful pregnancy
- Understand limitations of genetic testing
- Consider implications of genetic testing in case of late onset disorders (eg Huntington's; BRCA1 & BRCA2)
- Receive written summary, along with relevant information leaflets



# Preimplantation Genetic Testing

## Laboratory Tests for Chromosomal Abnormalities




**INTERNATIONAL FEDERATION OF FERTILITY SOCIETIES**  
Fédération internationale des sociétés de fertilité  
Federación internacional de sociedades de fertilidad

[www.iffs-reproduction.org](http://www.iffs-reproduction.org)

# First amplify the DNA

## Whole Genome Amplification (WGA)




Trophoblast biopsy




Blastomere biopsy



Polar body biopsy




# Array CGH (Comparative Genome Hybridisation)




- Compares DNA of the test cells with known normal karyotype
- Hybridise with oligo nucleotides on slide
- Limited resolution

# Translocation Analysis



# Next Generation Sequencing (NGS)



- Identification of chromosomal abnormalities *and* monogenic disorders
- Only labour and cost effective with high throughput
- Major implications with parallel sequencing options

# Arrays vs Next Generation Sequencing

	FISH	Micro Array	NGS
Sensitivity	Low	Medium	High
Coverage	1	3000 probes	150,000 reads
False positive rate	Moderate	Low	Very low
No. chromosomes tested	≤12	24	24
Detect single mutation?	No	No	Yes
Detection method	Indirect	Indirect	Direct






# Preimplantation Genetic Testing

## Strategies for embryo biopsy




# Strategies for embryo biopsy


Polar Body biopsy




Blastomere biopsy




Trophectoderm biopsy



# Strategies for embryo biopsy



Polar body biopsy




Blastomere biopsy



Trophoctoderm biopsy

# Breaching the zona pellucida

- Chemical – acid Tyrode's
  - Relatively cheap
  - Inter-procedure variables
  - Risk of exposure to chemical
- Mechanical – laser
  - Expensive
  - Programmed
  - Risk of heat damage



# Polar body analysis

- Polar bodies are the result of two meiotic divisions
- Polar bodies carry the complementary chromosomal content to the oocyte after each division
- Diagnosis only of oocyte
- **Only for disorders of maternal origin**





# Polar body analysis

- Removal of extra-embryonic DNA
- Allowed in countries where embryo testing is prohibited
- DNA from maximum 2 cells
- Technically challenging
- Polar bodies may fragment/degenerate




# Cleavage stage biopsy

- Day 3 biopsy; 6- to 8-cell stage
- Embryos may have compacted
- Pre-biopsy incubation in calcium-free medium
- Leave embryos in culture waiting for genetic analysis
- Biopsy embryos that may not develop
- Maximum 2 blastomeres biopsied
- Fresh embryo transfer on Day 5



# Blastocyst biopsy

- Current method of choice
- Breach zona on Day 3/4
- Allow trophectoderm to herniate
- Excise herniated TE cells
- Excise mechanically or using laser
- Biopsy 6-10 cells
- Cryopreserve biopsied blastocysts waiting for genetic analysis
- Only biopsy embryos that have developed into blastocysts
- Can “batch” genetic test runs – economy of scale
- Successful cryopreservation service essential





# Use of the Embryoscope



↑  
Ablated zona,  
awaiting herniation

↑  
Herniated cells,  
Ready for biopsy



# Some words of caution regarding PGS

- Is the biopsied material representative of the embryo?
- Might the embryo develop normally, even if some cells are chromosomally abnormal?
- Might PGS lead to some embryos being discarded when they might have corrected errors and developed normally?





INTERNATIONAL FEDERATION OF FERTILITY SOCIETIES  
[www.iffs-reproduction.org](http://www.iffs-reproduction.org)

# 2019 WORLD CONGRESS

Transforming the Frontiers of Human Reproduction



Shanghai

11 - 14 April 2019 | Shanghai Expo Centre | Shanghai, China

[www.iffs-reproduction.org](http://www.iffs-reproduction.org)



@IntFertilitySoc



Int@FedFertilitySoc